MENS says MCS-2 advances with FDA phase III approval
The company says MCS-2 advanced with FDA phase III approval for benign prostatic hyperplasia, and it describes the drug as a botanical option with a strong safety profile.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.